Market research
MYO Myomo, Inc
AMEX USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 55M
- P/E ratio
- Not available
- Analyst target
- 4.54
- Dividend yield
- Not available
- Beta
- 1.44
Profile
Company facts
- Exchange
- AMEX
- Currency
- USD
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- US62857J2015
- Market cap
- 55M
- P/E ratio
- Not available
- Analyst target
- 4.54
- Dividend yield
- Not available
- Beta
- 1.44
About
About Myomo, Inc
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. It also provides MyoPro 2 that includes control technology, configuration software and user interface, and pop-out battery for extended use of the brace; MyoPro2+, which comprises 3D printed orthotics capability, software enhancements, and a design for donning and doffing of the device; MyoGames, a virtual training platform; and MyoPro 2x Video Library. In addition, the company offers MyoCare, a post-delivery program that provides follow-up care with clients, therapists, and referral sources; MYOMO; MyoPal; and MyoCoach. Its products are designed to help adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products through various sales channels, including orthotics and prosthetics providers, veteran's administration, and distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Burlington, Massachusetts.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the MYO discussion.
5 years, 4 months ago
Myomo, Inc is currently in a long term uptrend where the price is trading 2.6% above its 200 day moving average.
From a valuation standpoint, the stock is 99.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 5.6.
Myomo, Inc's total revenue rose by 149.2% to $4M since the same quarter in the previous year.
Its net income has increased by 38.5% to $-2M since the same quarter in the previous year.
Finally, its free cash flow grew by 56.0% to $-1M since the same quarter in the previous year.
Based on the above factors, Myomo, Inc gets an overall score of 5/5.